Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
NCT07168993
This study is recruiting at 11 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, >6 to <30 mm in Diameter, Determined by LDCT.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Lung Cancer (Diagnosis)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- bioAffinity Technologies Inc.
- Last updated on ClinicalTrials.gov
- July 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- VA Palo Alto Health Care System · Palo Alto, CA
Colorado · 1
- VA Western Colorado Health Care System · Grand Junction, CO
Florida · 3
- Bay Pines VA Healthcare System · Bay Pines, FL
- Miami VA Healthcare System · Miami, FL
- James A. Haley Veterans' Hospital · Tampa, FL
Illinois · 1
- Captain James A. Lovell Federal Health Care Center · North Chicago, IL
Ohio · 1
- Dayton VA Medical Center · Dayton, OH
Pennsylvania · 1
- Clinical Research Associates of Central Pennsylvania · DuBois, PA
Texas · 2
- Audie Murphy VA Medical Center · San Antonio, TX
- Brooke Army Medical Center · San Antonio, TX
Wisconsin · 1
- Medical College of Wisconsin · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.